Oxygen Therapy
Newton · Founded 2016
About Oxygen Therapy
Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following a brain stroke. The Company’s lead product candidate, OTI-629, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, their drug candidate OTI-1011, will be tested as a resuscitative agent in a variety of wound healing applications.
Company Facts
- Founded: 2016
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $300.0K
- Funding stage: Seed
- Last round: Seed (Sep 2016)
- Website: otipharma.com
- Phone: 617-454-1199
Canonical: https://fsome.com/organization/oxygen-therapy-8443830 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.